Outcomes following brexucabtagene autoleucel administered as an FDA-approved therapy for adults with relapsed/refractory B-ALL. Roloff, G., Faramand, R., Aldoss, I., Kopmar, N., Schwartz, M., Dekker, S. E., Lin, C., Tracy, S., Vilchez, S., Dykes, K., O'Connor, T., Ahmed, M., Gupta, V. K., Ladha, A., Tsai, S., Leonard, J., Galal, A., Cassaday, R., Shah, B. D., Muffly, L. S. LIPPINCOTT WILLIAMS & WILKINS. 2023

View details for Web of Science ID 001053772003373